HCA Stock Recent News

J.P. Morgan research suggests the probability of a U.S. recession in 2025 is dropping below 50% from its 60% peak, now that the Trump administration is pulling punches on some of its more aggressive tariff policies, allowing the S&P 500 to rebound after dipping into correction territory back in March. However, the risk is still high.

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced a $5 million gift to the Thomas F. Frist, Jr. College of Medicine at Belmont University to support the Belmont Collaborative for Health Systems Innovation. Half of the gift will create the HCA Healthcare Health Systems Science Endowed Chair, and the other $2.5 million will be used for programmatic support in the Health Systems Science department. HCA Healthcare's.

HCA (HCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences: May 13, 2025 at 9:20am PT at the Bank of America 2025 Healthcare Conference. A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. Despite a market sell-off, my investable universe outperformed SPY and SCHD year-to-date, with a loss of -1.83% compared to -5.49% and -4.64%. This month, 17 stocks had valuation rating changes; 10 were upgrades, including Jack Henry & Associates, West Pharma, and EOG Resources, all with strong expected returns.

HCA (HCA) could produce exceptional returns because of its solid growth attributes.